Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

96
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
96
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

222
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
222
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

147
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
147

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcoidosis extent relates to molecular variability.

Clinical and experimental immunology·2017
Same author

Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.

Oncogene·2012
Same author

Motor protein Myo1c is a podocyte protein that facilitates the transport of slit diaphragm protein Neph1 to the podocyte membrane.

Molecular and cellular biology·2011
Same author

Effects of plasma proteins on sieving of tracer macromolecules in glomerular basement membrane.

American journal of physiology. Renal physiology·2001
Same author

Structural determinants of glomerular permeability.

American journal of physiology. Renal physiology·2001

Related Experiment Video

Updated: Apr 22, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling.

C S Monast1, M J Lazzara2

  • 1Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

CPT: Pharmacometrics & Systems Pharmacology
|October 16, 2014
PubMed
Summary

We modeled epidermal growth factor receptor (EGFR) phosphorylation to find factors influencing drug efficacy. Our findings reveal distinct mechanisms for kinase inhibitors and antibodies, guiding new therapeutic strategies.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Related Experiment Videos

Last Updated: Apr 22, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Computational Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial in cancer.
  • Targeting EGFR with kinase inhibitors (e.g., gefitinib) or antibodies (e.g., cetuximab) is a key therapeutic strategy.
  • Understanding the biochemical efficacy of these drugs is essential for optimizing cancer treatment.

Purpose of the Study:

  • To model cellular EGFR tyrosine phosphorylation dynamics.
  • To identify factors contributing to the biochemical efficacy of EGFR-targeting therapeutics.
  • To propose new drug design principles and therapeutic strategies.

Main Methods:

  • Development of a computational model for EGFR phosphorylation dynamics.
  • Simulation of gefitinib and cetuximab effects on EGFR phosphorylation.
  • Systematic analysis of factors influencing drug biochemical efficacy.

Main Results:

  • Distinct molecular processes control gefitinib and cetuximab biochemical efficacy.
  • Biochemical efficacy is influenced by specific EGFR ligands.
  • Gefitinib efficacy is sensitive to tyrosine phosphatase activity, while cetuximab efficacy is sensitive to ligand binding.

Conclusions:

  • Biochemical efficacy depends on factors beyond equilibrium binding affinities.
  • The model provides insights into optimizing EGFR-targeted therapies.
  • Predicted minimum therapeutic concentrations can maximally reduce EGFR phosphorylation.